Share: Facebook Twitter LinkedIn
Activity Provided By:

ACHL

The Emerging Science of Prophylactic Therapies for Migraine

Access Activity

Overview / Abstract:

Patients with frequent migraines and/or who experience functional disability need preventative migraine treatment. However, studies have shown that of the 38% of patients who stand to benefit from prophylactic therapy, only 3-13% of them actually receive it. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are under clinical investigation and constitute a new prophylactic migraine therapy class. Increased physician attention when individualizing treatment plans to maximize therapy efficacy and minimize side effects as well as managing headache triggers and existing comorbidities continue to be vital strategies as new agents emerge and when maximizing patient function.

Expiration

Dec 29, 2017

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Webinar / Webcast / Video

Credits / Hours

1.00 AMA PRA Category 1 Credit

Accreditation

ACHL

Presenters / Authors / Faculty

Mayo Clinic, Deborah I. Friedman, MD, MPH, FAHS, and
Stewart J. Tepper, MD, FAHS

Sponsors / Supporters / Grant Providers

Lilly

Keywords / Search Terms

ACHL CGRP, chronic migraine, Lilly, CME, chronic, disorder, sensitivity, migraine, chronic Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map